Abstract
Cancer patients often exhibit immunosuppression that is caused by the expanding tumor mass. This fact has severely compromised many efforts to develop effective cancer vaccines in the past. However, a new generation of immunotherapies takes focus on both activating the effector cells of the immune system as well as reverting the immunosuppression. This two-step process has lead to impressive anti-tumor effects both in experimental settings as well as in initial clinical trials. With new and powerful techniques for genetic engineering, the transfer of immunostimulating genes has gained interest. Genetic engineering of the tumor micromilieu has, for example, shown to be an effective means for breaking tumor-induced immunosuppression in an experimental model of bladder cancer. Genetic engineering can also be used to modify the immune effector cells to efficiently target tumor cells and to simultaneously resist immune inhibition. This review will discuss the immunological status of cancer patients with focus on T regulatory cells and their inhibitory cytokines as well as offer a survey of novel immune strategies for cancer gene therapy.
Keywords: Gene therapy, cancer vaccine, genetic engineering, immunotherapy, DC vaccine, T regulatory cells
Current Cancer Therapy Reviews
Title: Genetic Engineering - A New Era for Cancer Immunotherapy?
Volume: 3 Issue: 3
Author(s): Angelica Loskog and Thomas H. Totterman
Affiliation:
Keywords: Gene therapy, cancer vaccine, genetic engineering, immunotherapy, DC vaccine, T regulatory cells
Abstract: Cancer patients often exhibit immunosuppression that is caused by the expanding tumor mass. This fact has severely compromised many efforts to develop effective cancer vaccines in the past. However, a new generation of immunotherapies takes focus on both activating the effector cells of the immune system as well as reverting the immunosuppression. This two-step process has lead to impressive anti-tumor effects both in experimental settings as well as in initial clinical trials. With new and powerful techniques for genetic engineering, the transfer of immunostimulating genes has gained interest. Genetic engineering of the tumor micromilieu has, for example, shown to be an effective means for breaking tumor-induced immunosuppression in an experimental model of bladder cancer. Genetic engineering can also be used to modify the immune effector cells to efficiently target tumor cells and to simultaneously resist immune inhibition. This review will discuss the immunological status of cancer patients with focus on T regulatory cells and their inhibitory cytokines as well as offer a survey of novel immune strategies for cancer gene therapy.
Export Options
About this article
Cite this article as:
Angelica Loskog and Thomas H. Totterman , Genetic Engineering - A New Era for Cancer Immunotherapy?, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368341
DOI https://dx.doi.org/10.2174/157339407781368341 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Insights Into c-Src
Current Pharmaceutical Design PDE5 Inhibitor Treatment Options for Urologic and Non-Urologic Indications: 2012 Update
Current Pharmaceutical Design Cancer Stem Cell Model in Oral Squamous Cell Carcinoma
Current Stem Cell Research & Therapy Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol
Current Cancer Therapy Reviews Synthesis and Biological Evaluation of 1, 3-Dihydroxyxanthone Mannich Base Derivatives as Potential Antitumor Agents
Letters in Drug Design & Discovery New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome
Current Diabetes Reviews Vitamin D3 and Vitamin D3 Analogues as an Adjunct to Cancer Chemotherapy and Radiotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Multicomponent Reactions in Antimitotic Drug Discovery
Current Topics in Medicinal Chemistry Role of microRNA Deregulation in Breast Cancer Cell Chemoresistance and Stemness
Current Medicinal Chemistry DNA Repair Pathways and Human Metastatic Malignant Melanoma
Current Molecular Medicine Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics
Current Medicinal Chemistry Lyn Regulates Cytotoxicity in Respiratory Epithelial Cells Challenged by Cigarette Smoke Extracts
Current Molecular Medicine The Novel Synthesized Pyridazinone Derivates had the Antiproliferative and Apoptotic Effects in SHSY5Y and HEP3B Cancer Cell Line
Letters in Organic Chemistry Anti-Cancer Drug Design Using Natural and Synthetic Pharmacophores
Current Organic Chemistry Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry DNA Demethylation by TET Proteins: A Potential Therapeutic Target in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Studies on Efficacy of a Novel 177Lu-Labeled Porphyrin Derivative in Regression of Tumors in Mouse Model
Current Radiopharmaceuticals Hypoxia: Targeting the Tumour
Anti-Cancer Agents in Medicinal Chemistry TRPV1 Activation is Not An All-Or-None Event: TRPV1 Partial Agonism/Antagonism and Its Regulatory Modulation
Current Topics in Medicinal Chemistry Current Hydrogel Solutions for Repairing and Regeneration of Complex Tissues
Current Medicinal Chemistry